EssilorLuxottica S.A.
Designs, manufactures and distributes ophthalmic lenses, frames, sunglasses, diagnostic imaging equipment and eyecare instruments globally under brands including Ray-Ban, Oakley and Essilor.
As of Aug 31, 2026
Summary
EssilorLuxottica S.A. is a global leader in eyewear and lenses, combining optical manufacturing with luxury eyewear brands. The stock carries a bearish technical bias despite a 2.4 percent gain today, and has lost 35.8 percent over the past year. At €161.35, the company holds a market capitalisation of €74.1 billion.
Price history
As of Aug 28, 2026
Performance
+0.06%
-1.13%
-1.38%
-5.70%
-38.81%
-35.76%
As of Aug 28, 2026
Technical indicators
- 44.6
- -0.42Bearish
- 50: 166.76 · 200: 210.89Bearish
- €161.05 / €176.25
Technical Bias
Bearish lean
EssilorLuxottica's technical indicators are tilted bearish right now. The MACD shows downward momentum whilst the price sits below both the 50-day and 200-day moving averages, signalling a weak intermediate trend; RSI sits neutral. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Aug 28, 2026
Fundamentals
- €74.1B
- 30.1
- €5.36
- 8.52%
- +5.7%
- €3.77B
- 0.55
- €156.15 – €316.32
- 2.54%
- May 5, 2026
- Feb 11, 2027 (163 days)
As of Aug 31, 2026
Upcoming catalysts
- Earnings report
As of Aug 31, 2026
Latest news
As of Aug 31, 2026
MonkeyTrade's Take on EssilorLuxottica S.A.
Short-term outlook
The short-term technical read on EssilorLuxottica leans bearish, with MACD in negative territory and price sitting below both the 50-day (€166.76) and 200-day (€210.89) averages, though RSI at 44.6 keeps momentum from looking oversold. A break below €161.05 support would reinforce the downside case, while a reclaim of €176.25 resistance would be needed to challenge it. No earnings catalyst is imminent, with the next report not due until February 2027.
Medium-term outlook
EssilorLuxottica's fundamentals are steady rather than exciting: revenue growth of +5.7%, an 8.5% profit margin and a +2.5% dividend yield look solid, but a 30.1 P/E leaves little room for error, and the bearish technical lean suggests the market is already questioning that premium. Over the next few quarters we'd lean cautious, with the balance tilted toward further softness unless revenue growth accelerates meaningfully from current levels.
Key risks
- The stock is trading near its 52-week low of €161.35, far below the €316.32 high, suggesting significant negative momentum or a reassessment of valuation by the market.
- A reported succession dispute involving the founder's family could point to governance or leadership instability at the top of the company.
- The buyback programme's dilution catch highlights that share repurchases may not meaningfully reduce share count, potentially limiting the intended benefit to shareholders.
- With a price-to-earnings ratio of 30.1, the stock carries a premium valuation that leaves less room for error if growth or margins disappoint.
About EssilorLuxottica S.A.
EssilorLuxottica S.A. is a global leader in eyewear, bringing together lens-making expertise and iconic eyewear brands under one roof. Listed on Euronext Paris under the ticker EL, the group sits within the Healthcare sector, specifically Medical Instruments & Supplies, reflecting its role in vision care alongside its fashion and lifestyle eyewear lines. With a market capitalisation of €74.1 billion, it ranks among the larger names in its industry, giving it scale in manufacturing, distribution and retail across the eyewear value chain.
Its key figures point to a business valued at a premium, with a price-to-earnings ratio of 30.1 suggesting investors are pricing in steady, established demand rather than a bargain valuation. The dividend yield of +2.5% shows the company returns a portion of profits to shareholders, offering a modest income component alongside any share price movement.
How to trade EssilorLuxottica S.A.
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.